SCHEMBL2285404

SCHEMBL2285404

Cc1cc(O)c(C(=O)/C=C/c2cccc(C(=O)O)c2)c(=O)n1C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P4HB P07237 3/20 0.53
TTR P02766 2/20 0.48
SLC5A1 P13866 1/20 0.45
SLC5A2 P31639 1/20 0.45
MAOB P27338 2/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAOA P21397 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2285409 1.00 P4HB (0.53) P4HBTTRSLC5A1SLC5A2MAOB
SCHEMBL5630005 0.88 P4HB (0.58) P4HBMAOBCYP19A1CYP2C9MAOA
SCHEMBL5630008 0.88 P4HB (0.58) P4HBMAOBCYP19A1CYP2C9MAOA
SCHEMBL15233123 0.87 MAOA (0.49) SLC5A1SLC5A2MAOBCYP19A1CYP2C9
SCHEMBL2281390 0.87 MAOA (0.51) P4HBSLC5A1SLC5A2MAOBCYP19A1
SCHEMBL2281391 0.87 MAOA (0.51) P4HBSLC5A1SLC5A2MAOBCYP19A1
SCHEMBL2281539 0.87 P4HB (0.46) P4HBMAOBCYP19A1CYP2C9MAOA
SCHEMBL2284353 0.85 NPC1 (0.42) P4HBSLC5A1SLC5A2MAOBCYP19A1
SCHEMBL2284349 0.85 NPC1 (0.42) P4HBSLC5A1SLC5A2MAOBCYP19A1
SCHEMBL2281180 0.85 P4HB (0.44) P4HBMAOBCYP19A1CYP2C9MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 P4HB 702/4885TTR 3910/4885SLC5A1 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.